PCV 24 - Shanghai Reinovax Biologics
Alternative Names: 24-valent Pneumococcal Polysaccharide Conjugate Vaccine - Shanghai Reinovax Biologics; PCV-24 - Shanghai Reinovax Biologics; RZ-700Latest Information Update: 19 Jan 2026
At a glance
- Originator Shanghai Reinovax Biologics
- Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumococcal infections
Most Recent Events
- 11 Sep 2025 Phase-II clinical trials in Pneumococcal infections (In infants, In children, Prevention) in China (IM) (NCT07333352)
- 15 Nov 2024 Shanghai Reinovax Biologics completes a phase-I trial in Pneumococcal infections (Prevention) in China (IM) (NCT06678607)
- 27 Apr 2024 Phase-I clinical trials in Pneumococcal infections (Prevention, In children, In adolescents) in China (IM) (NCT06675032)